Pfizer and UCB have formed a new technology company, Cyclofluidic, established with the goal of accelerating the drug discovery process by allowing researchers to test a broader range of potential new drug in less time. The UK Government’s Technology Strategy Board helped to facilitate this arrangement between the two companies and will continue to support Cyclofluidic by co-funding its R&D. The new company will be jointly owned by Pfizer and UCB. Cyclofluidic’s goal is to develop technolog...